Original Article The combination of pralsetinib and bevacizumab enhances antitumor activity against KIF5B-RET lung cancer via PI3K/AKT pathway Xia Wang, Gaofeng Yuan, Li Cong, Zhen Song, Lili Lin, Zhugen Cao
